Chengdu Zeling Biomedical Technology Co. Ltd. has disclosed NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, inflammatory, autoimmune, cardiovascular, renal, gastrointestinal, respiratory and neurological disorders.

Genetic Intelligence Inc. has described compounds acting as IL-2 expression or activity modulators reported to be useful for the treatment of cancer, infections, autoimmune diseases and inflammatory disorders.

Ventus Therapeutics US Inc. has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, metabolic diseases, autoimmune diseases, and liver, renal, respiratory, cardiovascular and inflammatory disorders, among others.

Incyte Corp. has identified tyrosine-protein kinase JAK2 (V617F mutant) inhibitors reported to be useful for the treatment of cancer, hypereosinophilic syndrome, systemic mastocytosis and essential thrombocythemia, among others.

Insilico Medicine Inc. has synthesized fibroblast growth factor receptor 2 (FGFR2) and/or FGFR3 inhibitors reported to be useful for the treatment of cancer.

Shandong New Time Pharmaceutical Co. Ltd. has disclosed compounds acting as Bruton tyrosine kinase (BTK) inhibitors reported to be useful for the treatment of cancer and autoimmune diseases.

Researchers at McGill University and Neurasic Therapeutics Inc. have described substituted thiophene fused cyclohexanone derivatives acting as acid-sensing ion channel 1 (ASIC1) blockers reported to be useful for the treatment of pain, particularly neuropathic and inflammatory pain.

Primemupharma Co. Ltd. has divulged compounds comprising a novel polyester linker acting as antioxidants reported to be useful for the treatment of hearing loss and Meniere’s disease.

Shanghai Helioson Pharmaceutical Co. Ltd. has identified molecular glue degraders acting as DNA-binding protein Ikaros (IKZF1) and/or zinc finger protein Aiolos (IKZF3) degradation inducers reported to be useful for the treatment of cancer, autoimmune disease and inflammatory disorders.

Insilico Medicine Inc. has synthesized NLRP3 inflammasome inhibitors reported to be useful for the treatment of obesity, autoimmune disease and inflammatory disorders.